{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:59:50Z","timestamp":1792281590278,"version":"4.4.0"},"reference-count":165,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mayocp.2026.07.019","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:32:17Z","timestamp":1790836337000},"page":"1788-1817","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment of Breast Cancer"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6298-332X","authenticated-orcid":false,"given":"Kathryn J.","family":"Ruddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dam\u00e9","family":"Idossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalliah M.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly S.","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cathcart-Rake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara C.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib1","first-page":"477","article-title":"Breast cancer statistics 2024","volume":"74","author":"Giaquinto","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib2","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib3","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.31557\/APJCP.2024.25.8.2703","article-title":"Impact of Covid-19 on breast cancer screening","volume":"25","author":"Stevanato","year":"2024","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib4","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.3390\/ijms26072993","article-title":"Understanding susceptibility to breast cancer: from risk factors to prevention strategies","volume":"26","author":"Garc\u00eda-Sancha","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.mayocp.2018.03.025","article-title":"Updates in the evaluation and management of breast cancer","volume":"93","author":"O'Sullivan","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib6","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.23.02225","article-title":"Germline testing in patients with breast cancer: ASCO-Society of Surgical Oncology Guideline","volume":"42","author":"Bedrosian","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/his.14091","article-title":"WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast","volume":"77","author":"Tan","year":"2020","journal-title":"Histopathology"},{"issue":"25","key":"10.1016\/j.mayocp.2026.07.019_bib9","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1200\/JCO.2015.60.8133","article-title":"Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 Trial","volume":"33","author":"Metzger Filho","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/srao.2002.35249","article-title":"Molecular markers in the diagnosis and staging of breast cancer","volume":"12","author":"Dillon","year":"2002","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/11782234241234418","article-title":"Standard-of-care treatment for HER2+ metastatic breast cancer and emerging therapeutic options","volume":"18","author":"Premji","year":"2024","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.mayocp.2026.07.019_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib13","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-481154","article-title":"New treatment approaches for triple-negative breast cancer","volume":"45","author":"Riaz","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib14","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/SLA.0000000000003071","article-title":"Implications for breast cancer restaging based on the 8th edition AJCC Staging Manual","volume":"271","author":"Plichta","year":"2020","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"6797","key":"10.1016\/j.mayocp.2026.07.019_bib17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2026.07.019_bib18","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.breast.2015.07.008","article-title":"Clinical implications of the intrinsic molecular subtypes of breast cancer","volume":"24","author":"Prat","year":"2015","journal-title":"Breast"},{"issue":"22","key":"10.1016\/j.mayocp.2026.07.019_bib19","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199511303332203","article-title":"Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer","volume":"333","author":"Fisher","year":"1995","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib20","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1245\/s10434-015-4758-y","article-title":"Contralateral prophylactic mastectomy: challenging considerations for the surgeon","volume":"22","author":"Angelos","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib21","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1245\/s10434-016-5443-5","article-title":"Contralateral prophylactic mastectomy (CPM) consensus statement from the American Society of Breast Surgeons: data on CPM outcomes and risks","volume":"23","author":"Boughey","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs no axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib24","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2412063","article-title":"Axillary surgery in breast cancer \u2014 primary results of the INSEMA trial","volume":"392","author":"Reimer","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1186\/s12885-017-3443-x","article-title":"Clinically node negative breast cancer patients undergoing breast conserving therapy, sentinel lymph node procedure versus follow-up: a Dutch randomized controlled multicentre trial (BOOG 2013-08)","volume":"17","author":"van Roozendaal","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12885-022-09273-1","article-title":"No axillary surgical treatment for lymph node-negative patients after ultra-sonography [NAUTILUS]: protocol of a prospective randomized clinical trial","volume":"22","author":"Jung","year":"2022","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib28","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1001\/jamaoncol.2025.0207","article-title":"Selective elimination of breast surgery for invasive breast cancer: a nonrandomized clinical trial","volume":"11","author":"Kuerer","year":"2025","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib29","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.acra.2023.05.019","article-title":"Breast cancer cryoablation fundamentals past and present: technique optimization and imaging pearls","volume":"30","author":"Huang","year":"2023","journal-title":"Acad Radiol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib30","doi-asserted-by":"crossref","first-page":"7273","DOI":"10.1245\/s10434-024-16181-0","article-title":"Cryoablation without excision for early-stage breast cancer: ICE3 trial 5-year follow-up on ipsilateral breast tumor recurrence","volume":"31","author":"Fine","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"9804","key":"10.1016\/j.mayocp.2026.07.019_bib31","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","year":"2011","journal-title":"Lancet"},{"issue":"9935","key":"10.1016\/j.mayocp.2026.07.019_bib32","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(14)60488-8","article-title":"Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials","volume":"383","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib33","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.mayocp.2026.07.019_bib34","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10237","key":"10.1016\/j.mayocp.2026.07.019_bib36","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"issue":"10394","key":"10.1016\/j.mayocp.2026.07.019_bib37","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/S0140-6736(23)00619-0","article-title":"Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial","volume":"401","author":"Coles","year":"2023","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.mayocp.2026.07.019_bib38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.mayocp.2026.07.019_bib39","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa2412225","article-title":"Ten-year survival after postmastectomy chest-wall irradiation in breast cancer","volume":"393","author":"Kunkler","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2024.07.002","article-title":"A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505)","volume":"120","author":"Poppe","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib41","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jamaoncol.2024.2652","article-title":"Hypofractionated vs conventionally fractionated postmastectomy radiation after implant-based reconstruction: a randomized clinical trial","volume":"10","author":"Wong","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib42","article-title":"Comparison of deep inspiration breath hold versus free breathing in radiotherapy for left sided breast cancer","volume":"12","author":"Lu","year":"2022","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2026.07.019_bib43","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2007.15.2488","article-title":"A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis","volume":"26","author":"Pignol","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib44","article-title":"Assessment of proton beam therapy use among patients with newly diagnosed cancer in the US, 2004-2018","volume":"5","author":"Nogueira","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-025556","article-title":"RadComp (Radiotherapy Comparative Effectiveness Consortium). Pragmatic randomised clinical trial of proton versus photon therapy for patients with non-metastatic breast cancer: the Radiotherapy Comparative Effectiveness (RadComp) Consortium trial protocol","volume":"9","author":"Bekelman","year":"2019","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib46","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S1470-2045(25)00194-9","article-title":"Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial","volume":"26","author":"Kirby","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib47","article-title":"Financial toxicity of partial versus whole breast irradiation: a systematic review","volume":"9","author":"Brinjikji","year":"2025","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib48","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJMoa2302344","article-title":"Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer","volume":"389","author":"Whelan","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1056\/NEJMoa0906260","article-title":"Long-term results of hypofractionated radiation therapy for breast cancer","volume":"362","author":"Whelan","year":"2010","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib50","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00066-025-02481-1","article-title":"Breast Cancer Expert Panel of the German Society of Radiation Oncology DEGRO. DEGRO statement on the FAST-Forward trial: 10-year data of ultrahypofractionated radiation therapy for breast cancer","volume":"202","author":"Matuschek","year":"2026","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib52","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s00066-020-01730-9","article-title":"Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial","volume":"197","author":"Krug","year":"2021","journal-title":"Strahlenther Onkol"},{"issue":"1173","key":"10.1016\/j.mayocp.2026.07.019_bib53","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/bjr\/tqaf157","article-title":"Hypofractionated whole-breast radiation therapy with simultaneous integrated boost after breast-conserving surgery: preliminary real-life experience of the Radiation Therapy Oncology Group 1005 trial","volume":"98","author":"Loganadane","year":"2025","journal-title":"Br J Radiol"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib54","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","article-title":"Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis","volume":"2","author":"Spring","year":"2016","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2026.07.019_bib55","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib56","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JOP.18.00617","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update","volume":"15","author":"Burstein","year":"2019","journal-title":"J Oncol Pract"},{"issue":"22","key":"10.1016\/j.mayocp.2026.07.019_bib57","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","article-title":"Tamoxifen in the treatment of breast cancer","volume":"339","author":"Osborne","year":"1998","journal-title":"N Engl J Med"},{"issue":"9114","key":"10.1016\/j.mayocp.2026.07.019_bib58","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials","volume":"351","year":"1998","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib59","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","article-title":"Symptoms associated with tamoxifen treatment in postmenopausal women","volume":"151","author":"Love","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mayocp.2026.07.019_bib60","series-title":"US Food and Drug Administration Drug Label","year":"2019"},{"issue":"10001","key":"10.1016\/j.mayocp.2026.07.019_bib61","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib62","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN Guidelines\u00ae Insights: Breast Cancer, Version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib64","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib65","series-title":"Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: results from the global Phase III lidERA Breast Cancer trial","author":"Bardia","year":"2025"},{"issue":"suppl 16","key":"10.1016\/j.mayocp.2026.07.019_bib66","volume":"40","author":"Fasching","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib67","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamaoncol.2022.1488","article-title":"Treatment with adjuvant abemaciclib plus endocrine therapy in patients with high-risk early breast cancer who received neoadjuvant chemotherapy: a prespecified analysis of the monarchE randomized clinical trial","volume":"8","author":"Martin","year":"2022","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.019_bib68","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib69","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","article-title":"monarchE Committee Members. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study","volume":"33","author":"Rugo","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib70","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10549-020-06029-y","article-title":"Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials","volume":"186","author":"Goetz","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"10.1016\/j.mayocp.2026.07.019_bib71","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib72","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2340\/1651-226X.2025.43208","article-title":"CYP2D6 genotype and outcome in tamoxifen treated early breast cancer","volume":"64","author":"Thor\u00e9n","year":"2025","journal-title":"Acta Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib73","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.18.00307","article-title":"Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study","volume":"37","author":"Sanchez-Spitman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10503","key":"10.1016\/j.mayocp.2026.07.019_bib74","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0140-6736(25)01013-X","article-title":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"9869","key":"10.1016\/j.mayocp.2026.07.019_bib75","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib76","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdz289","article-title":"Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial","volume":"30","author":"Bartlett","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib77","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1056\/NEJMoa2104162","article-title":"Austrian Breast and Colorectal Cancer Study Group. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer","volume":"385","author":"Gnant","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib78","article-title":"Selection of patients with early-stage breast cancer for extended endocrine therapy: a secondary analysis of the IDEAL randomized clinical trial","volume":"7","author":"van 't Veer","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"24","key":"10.1016\/j.mayocp.2026.07.019_bib79","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mayocp.2026.07.019_bib80","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1200\/JCO.19.03120","article-title":"Management of male breast cancer: ASCO guideline","volume":"38","author":"Hassett","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib81","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib82","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib83","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2026.07.019_bib84","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.019_bib85","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.mayocp.2026.07.019_bib87","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","article-title":"Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18","author":"Wolmark","year":"2001","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib88","article-title":"NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel","volume":"11","author":"Mamounas","year":"1997","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib89","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10549-008-0050-1","article-title":"Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902","volume":"115","author":"van Nes","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"28","key":"10.1016\/j.mayocp.2026.07.019_bib90","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.mayocp.2026.07.019_bib91","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.1158\/0008-5472.CAN-20-1792","article-title":"Association of pathologic complete response with long-term survival outcomes in triple-negative breast cancer: a meta-analysis","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res"},{"issue":"16","key":"10.1016\/j.mayocp.2026.07.019_bib92","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1200\/JCO.22.02241","article-title":"Pathologic complete response and individual patient prognosis after neoadjuvant chemotherapy plus anti-human epidermal growth factor receptor 2 therapy of human epidermal growth factor receptor 2-positive early breast cancer","volume":"41","author":"van Mackelenbergh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.mayocp.2026.07.019_bib93","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib94","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.21037\/cco-20-123","article-title":"Neoadjuvant treatment for HER2-positive breast cancer","volume":"9","author":"Takada","year":"2020","journal-title":"Chin Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib96","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib97","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib98","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mayocp.2026.07.019_bib99","author":"Geyer","year":"2025"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.mayocp.2026.07.019_bib101","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib102","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103280","article-title":"Neoadjuvant chemotherapy in hormone receptor-positive\/HER2-negative early breast cancer: when, why and what?","volume":"160","author":"Torrisi","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib104","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","article-title":"Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial","volume":"6","author":"Nanda","year":"2020","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","article-title":"Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2\u2212 breast cancer: a randomized phase 3 trial","volume":"31","author":"Cardoso","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib106","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.mayocp.2026.07.019_bib107","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib108","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib109","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JCO.21.02937","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.mayocp.2026.07.019_bib110","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.mayocp.2026.07.019_bib111","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with \u22652 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib112","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.mayocp.2026.07.019_bib113","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.20.00775","article-title":"Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial","volume":"38","author":"Lin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib114","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.mayocp.2026.07.019_bib117","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib118","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib119","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib120","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib121","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamaoncol.2023.2000","article-title":"Cyclin-dependent kinase 4\/6 inhibitors for treatment of hormone receptor-positive, ERBB2-negative breast cancer: a review","volume":"9","author":"O'Sullivan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.mayocp.2026.07.019_bib122","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2026.07.019_bib123","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocp.2026.07.019_bib124","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocp.2026.07.019_bib125","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH Trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib126","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41416-021-01564-x","article-title":"ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges","volume":"126","author":"Herzog","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2026.07.019_bib127","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/cancers15051416","article-title":"Phosphoinositide 3-kinase (PI3K) inhibitors and breast cancer: an overview of current achievements","volume":"15","author":"Bertucci","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.mayocp.2026.07.019_bib128","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.mayocp.2026.07.019_bib129","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.mayocp.2026.07.019_bib130","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.019_bib131","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.019_bib132","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1093\/annonc\/mdu456","article-title":"Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2","volume":"25","author":"Piccart","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib133","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib134","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2026.07.019_bib135","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00109-021-02136-5","article-title":"Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies","volume":"99","author":"Saatci","year":"2021","journal-title":"J Mol Med (Berl)"},{"issue":"10411","key":"10.1016\/j.mayocp.2026.07.019_bib136","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib137","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib138","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib139","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.61067","article-title":"Survival following CDK4\/6 inhibitor therapy for hormone receptor-positive, ERBB2-negative metastatic breast cancer","volume":"8","author":"Berton Giachetti","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.mayocp.2026.07.019_bib140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"issue":"10265","key":"10.1016\/j.mayocp.2026.07.019_bib141","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.mayocp.2026.07.019_bib142","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2026.07.019_bib143","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib144","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejca.2023.01.031","article-title":"OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"184","author":"Robson","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.mayocp.2026.07.019_bib145","author":"Metzger","year":"2025"},{"key":"10.1016\/j.mayocp.2026.07.019_bib146","article-title":"HER2CLIMB-05: a phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","author":"Dieras","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10371","key":"10.1016\/j.mayocp.2026.07.019_bib147","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.mayocp.2026.07.019_bib148","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.mayocp.2026.07.019_bib149","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"20","key":"10.1016\/j.mayocp.2026.07.019_bib150","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.mayocp.2026.07.019_bib152","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib153","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.annonc.2024.04.013","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.mayocp.2026.07.019_bib154","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy\u2014MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib156","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib157","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","article-title":"Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival","volume":"32","author":"Slamon","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.mayocp.2026.07.019_bib158","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib159","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.annonc.2020.11.011","article-title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1","volume":"32","author":"Andr\u00e9","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.mayocp.2026.07.019_bib160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mayocp.2026.07.019_bib151","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","article-title":"Overall survival with palbociclib and fulvestrant in advanced breast cancer","volume":"379","author":"Turner","year":"2018","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mayocp.2026.07.019_bib161","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.mayocp.2026.07.019_bib162","unstructured":"FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. Accessed August 26 2026. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line?utm_source=chatgpt.com."},{"issue":"8","key":"10.1016\/j.mayocp.2026.07.019_bib163","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","volume":"37","author":"Dent","year":"2026","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.mayocp.2026.07.019_bib164","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2024.3056","article-title":"International Immuno-Oncology Biomarker Working Group. Tumor-infiltrating lymphocytes in triple-negative breast cancer","volume":"331","author":"Leon-Ferre","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.mayocp.2026.07.019_bib165","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221122725","article-title":"Clinical validity and clinical utility of Ki67 in early breast cancer","volume":"14","author":"Kreipe","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.mayocp.2026.07.019_bib166","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618656X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561962618656X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:54:06Z","timestamp":1792241646000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561962618656X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":165,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S002561962618656X"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.07.019","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2026.07.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}